TrialInternational journal of clinical oncology2023

First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.

Makoto Nishio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.